Biotechnology company Moderna (NASDAQ: MRNA) will be reporting results this Friday morning. Here’s what you need to know.

Moderna beat analysts’ revenue expectations last quarter, reporting revenues of $678 million, down 29.8% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.

Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Moderna’s revenue to grow 131% year on year, a reversal from the 35.3% decrease it recorded in the same quarter last year.

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing in majority downward revisions over the last 30 days. Moderna rarely misses Wall Street’s revenue estimates.

Looking at Moderna’s peers in the biotechnology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 1.9%, beating analysts’ expectations by 11.2%, and AbbVie reported revenues up 4.8%, falling short of estimates by 5.2%.

Read our full analysis of Biogen’s results here and AbbVie’s results here.

There has been positive sentiment among investors in the biotechnology segment, with share prices up 6.4% on average over the last month. Moderna is down 10.4% during the same time and is heading into earnings with an average analyst price target of $41.42 (compared to the current share price of $45.54).

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.